Predicted protein targets (top 15)
| gene | UniProt | supporting neighbours | confidence | |
|---|---|---|---|---|
| ▸ | LMNA | P02545 | 4/20 | 0.75 |
| ▸ | MEN1 | O00255 | 3/20 | 0.75 |
| ▸ | KMT2A | Q03164 | 3/20 | 0.75 |
| ▸ | NPSR1 | Q6W5P4 | 2/20 | 0.58 |
| ▸ | MAPT | P10636 | 1/20 | 0.58 |
| ▸ | GBA1 | P04062 | 11/20 | 0.58 |
| ▸ | SMN1; SMN2 | Q16637 | 1/20 | 0.55 |
| ▸ | POLB | P06746 | 1/20 | 0.52 |
| ▸ | TSHR | P16473 | 1/20 | 0.49 |
| ▸ | TP53 | P04637 | 1/20 | 0.46 |
| ▸ | ALDH1A1 | P00352 | 1/20 | 0.46 |
| ▸ | CYP1A2 | P05177 | 1/20 | 0.46 |
| ▸ | CYP2D6 | P10635 | 1/20 | 0.46 |
| ▸ | CYP2C9 | P11712 | 1/20 | 0.46 |
| ▸ | CYP2C19 | P33261 | 1/20 | 0.46 |
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| SCHEMBL7774642 | 0.98 | LMNA (0.73) | LMNAMEN1KMT2ANPSR1MAPT | |
| SCHEMBL8050942 | 0.92 | LMNA (0.69) | LMNAMEN1KMT2ANPSR1MAPT | |
| SCHEMBL7774828 | 0.89 | LMNA (0.65) | LMNAMEN1KMT2ANPSR1MAPT | |
| SCHEMBL9913722 | 0.85 | KMT2A (0.55) | LMNAMEN1KMT2ANPSR1MAPT | |
| SCHEMBL8054058 | 0.85 | TSHR (0.68) | LMNAMEN1KMT2AGBA1SMN1; SMN2 | |
| SCHEMBL7776363 | 0.83 | LMNA (0.57) | LMNAMEN1KMT2ANPSR1MAPT | |
| SCHEMBL9913696 | 0.82 | MEN1 (0.76) | LMNAMEN1KMT2ANPSR1MAPT | |
| SCHEMBL18404464 | 0.82 | LMNA (0.55) | LMNAMEN1KMT2ANPSR1MAPT | |
| SCHEMBL14725040 | 0.81 | TSHR (0.61) | LMNAMEN1KMT2AGBA1SMN1; SMN2 | |
| SCHEMBL14725034 | 0.81 | KMT2A (0.50) | LMNAMEN1KMT2ANPSR1MAPT |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 2 patents. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| US-8198387-B2 | Proton-conducting compound and proton-conducting polymer | NIPPON STEEL CHEMICAL CO., LTD. (JP) | 2012-06-12 | — | — | US | disclosed |
| US-20100063249-A1 | PROTON-CONDUCTING COMPOUND AND PROTON-CONDUCTING POLYMER | NIPPON STREEL CHEMICAL CO., LTD (JP) | 2010-03-11 | — | — | US | disclosed |
Patent text — is the patent's own abstract consistent with the prediction?
For each of this compound's patents that has machine-readable text (1 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.
| Patent | Title | Text reads most about | Predicted target · text-rank |
|---|---|---|---|
| US-20100063249-A1 | PROTON-CONDUCTING COMPOUND AND PROTON-CONDUCTING POLYMER | HRH3, H1-3, H1-4 | LMNA 1956/4885MEN1 27/4885KMT2A 799/4885 |
“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.